Reviewer's report

Title: Tamoxifen Use reduces Osteoporotic Fracture Risk in Asia Breast cancer woman: A nationwide population-based cohort study

Version: 3
Date: 16 March 2015
Reviewer: Andrew Cooke

Reviewer's report:

This article is of interest and I would recommend publication. The authors are to be commended for including comorbidities incl osteoporosis in model.

1. Minor: English grammar etc needs some minor edits

Discretionary revisions:

2. Methods: ER is not discussed. Is it not available from macro data? If not available then that limitation should be stated in methods. The absense of stage is mentioned in the discussion, but a line in methods would be helpful up front so that the limitation of macro data granularity is evident immediately.

3. Methods: prior HRT use? Is this available from the drug registry? If tam dose is available wouldn't HRT be available also?

Compulsory

4. (Major) Methods: Tamoxifen dose and duration are shown in the results but there is no mention in the methods how tamoxifen dose and duration is determined. Please provide a description

5. (Minor) Abstract: The age distribution of patients is required in the abstract to show this paper concerns both pre and postmenpausal subjects

6. (Minor) If tam dose and duration can be determined, then cannot AI dose and duration also be determined? Some further discussion of AI dose and its potential confounding should be added.

7. (Minor) Please mention if cross over [tam to AI] at 2-3 years may have occurred and how it might affect results.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I declare that I have no competing interests.